181 related articles for article (PubMed ID: 32193690)
21. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
22. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
23. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
24. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
[TBL] [Abstract][Full Text] [Related]
25. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
26. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
28. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
29. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL
Sci Rep; 2019 Feb; 9(1):2905. PubMed ID: 30814573
[TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
31. Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Belter A; Barciszewski J; Barciszewska AM
PLoS One; 2020; 15(2):e0229534. PubMed ID: 32101575
[TBL] [Abstract][Full Text] [Related]
32. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
33. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
34. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
35. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O
Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668
[TBL] [Abstract][Full Text] [Related]
36. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
[TBL] [Abstract][Full Text] [Related]
37. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
[TBL] [Abstract][Full Text] [Related]
38. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
39. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
40. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ
Front Genet; 2019; 10():910. PubMed ID: 31611911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]